Galmed Prescription drugs NASDAQ: GLMD, a little-known biotech inventory, has turn into the focus as its shares have skyrocketed near 400%. By 2 pm, the inventory had traded over 80 million shares, a monumental leap from its common day by day quantity of simply 75,000.

The sudden surge begs the query: What’s driving this small-cap biotech to such heights, and will traders think about leaping in?

First, What Is Galmed Prescription drugs?

Galmed Prescription drugs is a small-cap biopharmaceutical firm headquartered in Tel Aviv, Israel. Its main focus is growing therapeutics for liver ailments, primarily concentrating on non-alcoholic steatohepatitis (NASH). The corporate’s main product, Aramchol, is an oral remedy at present in Section III trials for treating NASH in sufferers with weight problems and kind II diabetes.

Galmed can also be investigating Aramchol for different circumstances, together with liver illness associated to HIV, through the ARRIVE examine. Moreover, the corporate is growing a 5-amino-acid artificial peptide, Amilo-5MER, and has partnerships with Samil Pharma and OnKai.

Why Did Galmed Surge Immediately?

Two key causes are behind as we speak’s dramatic surge in Galmed’s inventory worth, considered one of which is much extra vital than the opposite.

1) Regaining Nasdaq Compliance (Minor Catalyst) 

Galmed’s 6k SEC filing on September 16, 2024, revealed that the corporate had regained compliance with Nasdaq’s minimal bid worth requirement. Beforehand, the inventory had fallen under the $1.00 threshold for 30 consecutive days, placing it in peril of delisting. Whereas this information attracted consideration, it’s inadequate to clarify the explosive 400% rise. As a substitute, this announcement acted as a spark, bringing extra eyes to the inventory.

2) Brief Squeeze Pushed by Technical Components (Main Catalyst)

The actual driver behind the surge lies in Galmed’s distinctive inventory construction and buying and selling dynamics. The inventory is inclined to supply-demand imbalances, with a tiny float of solely round 600,000 shares. Immediately’s buying and selling quantity noticed an RVOL at 2 pm (Relative Quantity) of over 600, that means the inventory was buying and selling 600 instances greater than its common day by day quantity. When provide is that this restricted and demand spikes, because it did as we speak, shares can expertise epic brief squeezes, pushing costs larger in a brief interval.

The supply of inventory locates (shares obtainable for brief promoting) throughout numerous buying and selling platforms additional fueled the surge. Brief sellers, betting on the inventory’s decline, have persistently been compelled to purchase again shares at ever-increasing costs as demand vastly outweighs provide within the brief time period, making a textbook brief squeeze of huge proportions.

Is Galmed a Good Play for Lively Buyers Searching for Excessive Returns?

Whereas Galmed’s surge has captured consideration, the reply as to whether it is best to make investments largely relies on your threat tolerance. For long-term traders, the reply is probably going no. The inventory’s volatility, low liquidity, and susceptibility to dramatic worth swings make it higher fitted to short-term merchants who can capitalize on intraday strikes.

This inventory’s huge potential for each beneficial properties and losses makes it interesting for day merchants however harmful for these in search of a secure, long-term funding. The mix of a tiny float, buying and selling inefficiencies, and supply-demand imbalances implies that whereas the inventory may rise one other 200%, it may simply as rapidly retrace most of its intraday transfer.

Earlier than you think about Galmed Prescription drugs, you may wish to hear this.

MarketBeat retains monitor of Wall Road’s top-rated and finest performing analysis analysts and the shares they advocate to their shoppers every day. MarketBeat has recognized the 5 shares that high analysts are quietly whispering to their shoppers to purchase now earlier than the broader market catches on… and Galmed Prescription drugs wasn’t on the record.

Like this text? Share it with a colleague.

Hyperlink copied to clipboard.